Advertisement

Tumor Biology

, Volume 35, Issue 9, pp 9195–9200 | Cite as

Quantitative assessment of the associations between CD28 T > C polymorphism (rs3116496) and cancer risk

  • Jianjun Cong
  • Shulong Zhang
  • Xueren Gao
Research Article

Abstract

Many studies have examined the association between CD28 T > C polymorphism (rs3116496) and cancer risk in various populations. However, results remained controversial. To assess this relationship more precisely, a meta-analysis was performed. A comprehensive literature search was performed using the PubMed database for relevant articles published (updated to January 1, 2014). Odds ratios (ORs) and 95 % confidence intervals (CIs) were used to assess the strength of the association. A total of nine studies were selected for this meta-analysis, including 3,878 cases and 4,424 controls. The results indicated that CD28 T > C polymorphism (rs3116496) was not associated with the risk of cancer in overall population (CC + CT vs. TT, OR = 1.17, 95 %CI = 0.94–1.47, P H = 0.00; CC vs. CT + TT, OR = 1.26, 95 %CI = 0.92–1.73, P H = 0.86; CC vs. TT, OR = 1.27, 95 %CI = 0.92–1.74, P H = 0.85; CT vs. TT, OR = 1.15, 95 %CI = 0.91–1.46, P H = 0.00; and C vs. T, OR = 1.17, 95 %CI = 0.97–1.41, P H = 0.00). In subgroup analysis according to cancer type, no significant association was found in cervical cancer or other cancer. However, in the subgroup analysis by ethnicity, the significant risk was found among Asians (CC + CT vs. TT, OR = 1.51, 95 %CI = 1.24–1.83, P H = 0.05; C vs. T, OR = 1.46, 95 %CI = 1.22–1.74, P H = 0.11), but not among Caucasians. The result of this meta-analysis suggested that CD28 T > C polymorphism (rs3116496) may have an increased risk of cancer in Asians.

Keywords

CD28 Polymorphism Cancer risk Meta-analysis 

Notes

Conflicts of interest

None

References

  1. 1.
    Lesterhuis WJ, Haanen JB, Punt CJ. Cancer immunotherapy—revisited. Nat Rev Drug Discov. 2011;10:591–600.CrossRefPubMedGoogle Scholar
  2. 2.
    Rudd CE, Taylor A, Schneider H. CD28 and CTLA-4 coreceptor expression and signal transduction. Immunol Rev. 2009;229:12–26.PubMedCentralCrossRefPubMedGoogle Scholar
  3. 3.
    Collins M, Ling V, Carreno BM. The B7 family of immune-regulatory ligands. Genome Biol. 2005;6:223.PubMedCentralCrossRefPubMedGoogle Scholar
  4. 4.
    Kim HJ, Chung JH, Kang S, Kim SK, Cho BS, Kim SD, et al. Association of CTLA4, CD28 and ICOS gene polymorphisms with clinicopathologic characteristics of childhood IgA nephropathy in Korean population. J Genet. 2011;90:151–5.CrossRefPubMedGoogle Scholar
  5. 5.
    Hutloff A, Dittrich AM, Beier KC, Eljaschewitsch B, Kraft R, Anaqnostopoulos I, et al. ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28. Nature. 1999;397:263–6.CrossRefPubMedGoogle Scholar
  6. 6.
    Yoshinaga SK, Whoriskey JS, Khare SD, Sarmiento U, Guo J, Horan T, et al. Tcell co-stimulation through B7RP-1 and ICOS. Nature. 1999;402:827–32.CrossRefPubMedGoogle Scholar
  7. 7.
    Bouwhuis MG, Gast A, Figl A, Eggermont AM, Hemminki K, Schadendorf D, et al. Polymorphisms in the CD28/CTLA4/ICOS genes: role in malignant melanoma susceptibility and prognosis? Cancer Immunol Immunother. 2010;59:303–12.PubMedCentralCrossRefPubMedGoogle Scholar
  8. 8.
    Chen S, Zhang Q, Shen L, Liu Y, Xu F, Li D, et al. Investigation of CD28 gene polymorphisms in patients with sporadic breast cancer in a Chinese Han population in Northeast China. PLoS ONE. 2012;7:e48031.PubMedCentralCrossRefPubMedGoogle Scholar
  9. 9.
    Chen X, Li H, Qiao Y, Yu D, Guo H, Tan W, et al. Association of CD28 gene polymorphism with cervical cancer risk in a Chinese population. Int J Immunogenet. 2011;38:51–4.CrossRefPubMedGoogle Scholar
  10. 10.
    Cheng TY, Lin JT, Chen LT, Shun CT, Wang HP, Lin MT, et al. Association of T-cell regulatory gene polymorphisms with susceptibility to gastric mucosa-associated lymphoid tissue lymphoma. J Clin Oncol. 2006;24:3483–9.CrossRefPubMedGoogle Scholar
  11. 11.
    Dilmec F, Ozgonul A, Uzunkoy A, Akkafa F. Investigation of CTLA-4 and CD28 gene polymorphisms in a group of Turkish patients with colorectal cancer. Int J Immunogenet. 2008;35:317–21.CrossRefPubMedGoogle Scholar
  12. 12.
    Ivansson EL, Juko-Pecirep I, Gyllensten UB. Interaction of immunological genes on chromosome 2q33 and IFNG in susceptibility to cervical cancer. Gynecol Oncol. 2010;116:544–8.CrossRefPubMedGoogle Scholar
  13. 13.
    Karabon L, Pawlak E, Tomkiewicz A, Jedynak A, Passowicz-Muszynska E, Zajda K, et al. CTLA-4, CD28, and ICOS gene polymorphism associations with non-small-cell lung cancer. Hum Immunol. 2011;72:947–54.CrossRefPubMedGoogle Scholar
  14. 14.
    Pawlak E, Karabon L, Wlodarska-Polinska I, Jedynak A, Jonkisz A, Tomkiewicz A, et al. Influence of CTLA-4/CD28/ICOS gene polymorphisms on the susceptibility to cervical squamous cell carcinoma and stage of differentiation in the Polish population. Hum Immunol. 2010;71:195–200.CrossRefPubMedGoogle Scholar
  15. 15.
    Suwalska K, Pawlak E, Karabon L, Tomkiewicz A, Dobosz T, Urbaniak-Kujda D, et al. Association studies of CTLA-4, CD28, and ICOS gene polymorphisms with B-cell chronic lymphocytic leukemia in the Polish population. Hum Immunol. 2008;69:193–201.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  1. 1.Department of NeurosurgeryAffiliated Zhongshan Hospital of Dalian UniversityDalianChina
  2. 2.Department of General Surgery, Zhongda HospitalMedical School of Southeast UniversityNanjingChina
  3. 3.Department of Microbiology and ImmunologyMedical School of Southeast UniversityNanjingChina

Personalised recommendations